D.E. Shaw & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-4,718,246
| Closed | -$546M | – | 4792 |
|
|
2023
Q3 | $546M | Buy |
4,718,246
+1,035,866
| +28% | +$111M | 0.57% | 11 |
|
|
2023
Q2 | $379M | Buy |
3,682,380
+1,457,042
| +65% | +$154M | 0.39% | 22 |
|
|
2023
Q1 | $243M | Buy |
2,225,338
+2,145,248
| +2,679% | +$237M | 0.26% | 58 |
|
|
2022
Q4 | $9.11M | Sell |
80,090
-334,088
| -81% | -$27.7M | 0.01% | 1519 |
|
|
2022
Q3 | $25.6M | Buy |
414,178
+390,368
| +1,640% | +$27.3M | 0.03% | 710 |
|
|
2022
Q2 | $1.9M | Sell |
23,810
-246,964
| -91% | -$23.4M | ﹤0.01% | 3119 |
|
|
2022
Q1 | $28.5M | Buy |
270,774
+124,881
| +86% | +$12.2M | 0.03% | 807 |
|
|
2021
Q4 | $15.7M | Sell |
145,893
-109,344
| -43% | -$11.9M | 0.01% | 1260 |
|
|
2021
Q3 | $28M | Sell |
255,237
-169,464
| -40% | -$17.6M | 0.03% | 821 |
|
|
2021
Q2 | $39.8M | Sell |
424,701
-1,192,747
| -74% | -$110M | 0.03% | 653 |
|
|
2021
Q1 | $149M | Sell |
1,617,448
-686,298
| -30% | -$57.9M | 0.14% | 144 |
|
|
2020
Q4 | $169M | Sell |
2,303,746
-735,867
| -24% | -$54.7M | 0.15% | 131 |
|
|
2020
Q3 | $236M | Buy |
3,039,613
+67,181
| +2% | +$4.62M | 0.24% | 70 |
|
|
2020
Q2 | $165M | Sell |
2,972,432
-1,345,321
| -31% | -$57.6M | 0.2% | 90 |
|
|
2020
Q1 | $128M | Sell |
4,317,753
-816,404
| -16% | -$27.6M | 0.2% | 100 |
|
|
2019
Q4 | $186M | Buy |
5,134,157
+24,331
| +0.5% | +$746K | 0.21% | 93 |
|
|
2019
Q3 | $139M | Buy |
5,109,826
+11,897
| +0.2% | +$308K | 0.17% | 129 |
|
|
2019
Q2 | $123M | Buy |
5,097,929
+695,950
| +16% | +$17.7M | 0.15% | 146 |
|
|
2019
Q1 | $116M | Buy |
4,401,979
+1,032,471
| +31% | +$24.5M | 0.15% | 151 |
|
|
2018
Q4 | $65.8M | Buy |
3,369,508
+1,312,142
| +64% | +$25.7M | 0.09% | 260 |
|
|
2018
Q3 | $40.3M | Buy |
2,057,366
+1,277,249
| +164% | +$24.3M | 0.05% | 474 |
|
|
2018
Q2 | $12.9M | Buy |
780,117
+287,032
| +58% | +$4.38M | 0.02% | 942 |
|
|
2018
Q1 | $7M | Buy |
493,085
+139,210
| +39% | +$2.06M | 0.01% | 1202 |
|
|
2017
Q4 | $5.17M | Buy |
353,875
+330,281
| +1,400% | +$4.64M | 0.01% | 1464 |
|
|
2017
Q3 | $299K | Buy |
+23,594
| New | +$300K | ﹤0.01% | 3142 |
|
|
2017
Q2 | – | Sell |
-285,668
| Closed | -$4.22M | – | 3634 |
|
|
2017
Q1 | $4.22M | Sell |
285,668
-838,271
| -75% | -$13.6M | 0.01% | 1393 |
|
|
2016
Q4 | $18.2M | Buy |
1,123,939
+146,483
| +15% | +$2.66M | 0.03% | 665 |
|
|
2016
Q3 | $17.7M | Buy |
977,456
+49,942
| +5% | +$976K | 0.03% | 622 |
|
|
2016
Q2 | $15.3M | Buy |
927,514
+501,697
| +118% | +$8.12M | 0.03% | 652 |
|
|
2016
Q1 | $7.06M | Sell |
425,817
-275,789
| -39% | -$4.83M | 0.01% | 1061 |
|
|
2015
Q4 | $15.2M | Sell |
701,606
-2,395,068
| -77% | -$46.6M | 0.02% | 765 |
|
|
2015
Q3 | $61.4M | Buy |
3,096,674
+1,291,149
| +72% | +$40.8M | 0.09% | 272 |
|
|
2015
Q2 | $62.7M | Buy |
1,805,525
+248,502
| +16% | +$7.58M | 0.09% | 254 |
|
|
2015
Q1 | $40.4M | Buy |
1,557,023
+149,719
| +11% | +$2.74M | 0.06% | 368 |
|
|
2014
Q4 | $18.1M | Buy |
1,407,304
+1,308,771
| +1,328% | +$16.4M | 0.02% | 759 |
|
|
2014
Q3 | $1.21M | Sell |
98,533
-149,727
| -60% | -$1.74M | ﹤0.01% | 2652 |
|
|
2014
Q2 | $3.93M | Sell |
248,260
-548,864
| -69% | -$7.83M | 0.01% | 1795 |
|
|
2014
Q1 | $12.1M | Buy |
797,124
+335,894
| +73% | +$3.79M | 0.02% | 934 |
|
|
2013
Q4 | $3.51M | Buy |
461,230
+441,183
| +2,201% | +$2.38M | ﹤0.01% | 1989 |
|
|
2013
Q3 | $68K | Buy |
+20,047
| New | +$52.9K | ﹤0.01% | 4219 |
|
Other funds holding HZNP
D.E. Shaw & Co's HZNP Position: Q4 2023 in Review
D.E. Shaw & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,718,246 shares — an estimated $546M sold.
D.E. Shaw & Co first reported a position in HZNP in Q3 2013 and held it in 40 quarters. The position peaked at $546M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.
- D.E. Shaw & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
- D.E. Shaw & Co sold 4,718,246 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $546M.
- D.E. Shaw & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 40 quarters.
- D.E. Shaw & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $546M in Q3 2023.
- 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.
Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.